Tamoxifen for Five Years

Tamoxifen is an effective anti-cancer drug in breast cancer treatment. However, very few women could do the complete 5-year treatment due to the side effects of the medication. The irregular bleeding, osteoporosis, and hormonal imbalance symptoms always cut the time short. Since every woman is different in body weight, genetic compose, reproductive history, and personal habits, the treatment with tamoxifen should also be different. Moreover, since estrogen has the similar positive effects as Vitamin K2 in bone formation tamoxifen, as a estrogen blocker, should be used with proper vitamin K2 supplement, to which, current medical world has not paid enough attention.

Download Full-text

Tamoxifen for Five Years

International Journal of Cancer Research & Therapy ◽

10.33140/ijcrt.06.02.10 ◽

2021 ◽

Vol 6 (2) ◽

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Breast Cancer Treatment ◽

Vitamin K2 ◽

Current Medical ◽

Cancer Drug ◽

Positive Effects ◽

Hormonal Imbalance ◽

Anti Cancer ◽

Irregular Bleeding

Download Full-text

Effervescent floating matrix tablets of a novel anti-cancer drug neratinib for breast cancer treatment

Journal of Drug Delivery Science and Technology ◽

10.1016/j.jddst.2021.102788 ◽

2021 ◽

pp. 102788

Author(s):

Mohamed Rahamathulla ◽

Saad M. Alsahhrani ◽

Ahmed Al Saqr ◽

Abdullah Alshetaili ◽

Faiyaz Shakeel

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Breast Cancer Treatment ◽

Matrix Tablets ◽

Cancer Drug ◽

Anti Cancer

Download Full-text

Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect

Cancer Nanotechnology ◽

10.1186/s12645-021-00085-9 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Farnaz Dabbagh Moghaddam ◽

Iman Akbarzadeh ◽

Ehsan Marzbankia ◽

Mahsa Farid ◽

Leila khaledi ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Cell Lines ◽

Encapsulation Efficiency ◽

Inbred Mice ◽

Breast Cancer Treatment ◽

Anticancer Effect ◽

Anti Cancer

Abstract Background Melittin, a peptide component of honey bee venom, is an appealing candidate for cancer therapy. In the current study, melittin, melittin-loaded niosome, and empty niosome had been optimized and the anticancer effect assessed in vitro on 4T1 and SKBR3 breast cell lines and in vivo on BALB/C inbred mice. "Thin-layer hydration method" was used for preparing the niosomes; different niosomal formulations of melittin were prepared and characterized in terms of morphology, size, polydispersity index, encapsulation efficiency, release kinetics, and stability. A niosome was formulated and loaded with melittin as a promising drug carrier system for chemotherapy of the breast cancer cells. Hemolysis, apoptosis, cell cytotoxicity, invasion and migration of selected concentrations of melittin, and melittin-loaded niosome were evaluated on 4T1 and SKBR3 cells using hemolytic activity assay, flow cytometry, MTT assay, soft agar colony assay, and wound healing assay. Real-time PCR was used to determine the gene expression. 40 BALB/c inbred mice were used; then, the histopathology, P53 immunohistochemical assay and estimate of renal and liver enzyme activity for all groups had been done. Results This study showed melittin-loaded niosome is an excellent substitute in breast cancer treatment due to enhanced targeting, encapsulation efficiency, PDI, and release rate and shows a high anticancer effect on cell lines. The melittin-loaded niosome affects the genes expression by studied cells were higher than other samples; down-regulates the expression of Bcl2, MMP2, and MMP9 genes while they up-regulate the expression of Bax, Caspase3 and Caspase9 genes. They have also enhanced the apoptosis rate and inhibited cell migration, invasion in both cell lines compared to the melittin samples. Results of histopathology showed reduce mitosis index, invasion and pleomorphism in melittin-loaded niosome. Renal and hepatic biomarker activity did not significantly differ in melittin-loaded niosome and melittin compared to healthy control. In immunohistochemistry, P53 expression did not show a significant change in all groups. Conclusions Our study successfully declares that melittin-loaded niosome had more anti-cancer effects than free melittin. This project has demonstrated that niosomes are suitable vesicle carriers for melittin, compare to the free form.

Download Full-text

Antitumor effects of Auraptene in 4T1 tumor‐bearing Balb/c mice

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2020-0090 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Mohammad Reza. Shiran ◽

Davar Amani ◽

Abolghasem Ajami ◽

Mahshad Jalalpourroodsari ◽

Maghsoud Khalizadeh ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Tumor Volume ◽

Serum Levels ◽

Ki 67 ◽

Tumor Bearing ◽

Paraffin Oil ◽

Anti Cancer ◽

Before And After ◽

Ifn Γ

Abstract Objectives Breast cancer is a common malignant tumor in women with limited treatment options and multiple side effects. Today, the anti-cancer properties of natural compounds have attracted widespread attention from researchers worldwide. Methods In this study, we treated 4T1 tumor-bearing Balb/c mice with intraperitoneal injection of Auraptene, paraffin oil, and saline as two control groups. Body weight and tumor volume were measured before and after treatment. Hematoxylin and eosin (H & E) staining and immunohistochemistry of Ki-67 were used as markers of proliferation. In addition, ELISA assays were performed to assess serum IFN-γ and IL-4 levels. Results There was no significant change in body weight in all animal groups before and after treatment. 10 days after the last treatment, Auraptene showed its anti-cancer effect, which was confirmed by the smaller tumor volume and H & E staining. In addition, Ki-67 expression levels were significantly reduced in tumor samples from the Auraptene-treated group compared to the paraffin oil and saline-treated groups. In addition, in tumor-bearing and normal mice receiving Auraptene treatment, IL-4 serum production levels were reduced, while serum levels of IFN-γ were significantly up-regulated in tumor-bearing mice after Auraptene treatment. Conclusions In the case of inhibition of tumor volume and Ki-67 proliferation markers, Auraptene can effectively inhibit tumor growth in breast cancer animal models. In addition, it might increases Th1 and CD8 + T cell responses after reducing IL-4 serum levels and IFN-γ upregulation, respectively. However, further research is needed to clarify its mechanism of action.

Download Full-text

Prevascularized, Co-Culture Model for Breast Cancer Drug Development

ASME 2012 Summer Bioengineering Conference, Parts A and B ◽

10.1115/sbc2012-80409 ◽

2012 ◽

Author(s):

Lauren Marshall ◽

Isabel Löwstedt ◽

Paul Gatenholm ◽

Joel Berry

Keyword(s):

Breast Cancer ◽

Drug Development ◽

Three Dimensional ◽

Human Tumor ◽

3D Models ◽

Cancer Drug ◽

Cancer Therapies ◽

Anti Cancer

The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of whom cannot afford it. An emerging paradigm in pharmaceutical drug development is the use of three-dimensional (3D) cell/biomaterial models that will accurately screen novel therapeutic compounds, repurpose existing compounds and terminate ineffective ones. In particular, identification of effective chemotherapies for breast cancer are anticipated to occur more quickly in 3D in vitro models than 2D in vitro environments and in vivo animal models, neither of which accurately mimic natural human tumor environments [2]. Moreover, these 3D models can be multi-cellular and designed with extracellular matrix (ECM) function and mechanical properties similar to that of natural in vivo cancer environments [3].

Download Full-text

A small molecule LN435a targeting TGFβR1 exerts promising antitumor effects on breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e15069 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e15069-e15069

Author(s):

Yuzhu Zhang ◽

Huachao Li ◽

Hongyan Zhang ◽

Xiaoyuan Liu ◽

Tianyu Luo ◽

...

Keyword(s):

Breast Cancer ◽

Stem Cell ◽

Anticancer Activity ◽

Multiple Drug Resistance ◽

Cancer Drug ◽

Her2 Status ◽

Stem Cell Markers ◽

Antitumor Effects ◽

Cell Markers ◽

Anti Cancer

e15069 Background: Breast cancer has overtaken lung cancer as the most diagnosed cancer. Despite conventional treatment, metastases occur in 20-30% of patients, resulting in death. This study aims to screen of effective drugs by metastatic patient-derived organoid and the potential molecular mechanism. Methods: Breast Cancer patient-derived organoid (PDO) model was established from the patient who have multiple drug resistance, multiple visceral and contralateral breast metastases. The organoid morphologies was tested by hematoxylin-eosin (HE) staining and immunohistochemistry (IHC). Then, pharmacological activity assay of 2370 natural product monomer (from Selleck) was performed with organoids. we modified the structure of harmine(HM) and screened the best active drugs. Cell proliferation assay and wound healing assay were used to detect LN435a anticancer activity in vitro. Orthotopic, Metastatic Xenograft and Patient-Derived tumor Xenograft(PDX) model of Breast Cancer were used to detect LN435a anticancer activity in vivo. In order to explore the anti-cancer target of LN435a, we used RNA transcriptome and proteomics sequencing. To further validate anti-cancer targets,TGFβ receptor 1 (TGFβR1), we used real-time quantitative qPCR, western blot, lentiviral packing and biolayer interferometry assay. To investigate whether LN435a inhabition of EMT and stem cell markers, we performed flow cytometry, immunohistochemistry and fluorescence. Results: We observe that organoid morphologies typically matched the histopathology, hormone receptor status, and HER2 status of the original tumor. In the first anti-cancer drug screening, HM showes the best effect on PDO. Because HM contains β-carbine alkaloids as the structural units, we designe a series of active drugs based on this and did anticancer screening. We find LN435a as one of the lead compounds exerting anti-metastatic activity in the nanomolar range in PDO and breast cancer cells. Proteomic and biochemical studies identify TGFβR1 as the direct target of LN435a. And then it inhibits EMT and stem cell markers. In parallel, loss of TGFβR1 or pharmacological inhibition of TGFβR1 by LN435a reduces breast cancer extravasation into the lung in an experimental metastasis mouse model, which reveals an essential role of TGFβR1 in breast cancer progression. Conclusions: Altogether, LN435a is a novel inhibitor of promising anti-tumor effects on breast cancer that works by blocking TGFβ signaling pathways.

Download Full-text

Research Progress of Geraniol in Tumor Therapy

Proceedings of Anticancer Research ◽

10.26689/par.v5i1.1882 ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Hao Zhi ◽

Jianying Cui ◽

Hongli Yang ◽

Yonggang Zhang ◽

Meng Zhu

Keyword(s):

Breast Cancer ◽

Tumor Therapy ◽

Pharmacological Action ◽

Research Progress ◽

Good Effect ◽

Cancer Drug ◽

Aromatic Plants ◽

Anti Cancer ◽

Different Types ◽

Cancer Côlon

Geraniol is an acyclic monoterpenoid compound, which exists widely in aromatic plants. Geraniol has antibacterial and anti-inflammatory effects. Recently, it has been found that geraniol has a strong effect on improving immune function and anti-tumor. Many experimental evidences support that geraniol has a good effect on the treatment or prevention of different types of tumors, such as breast cancer, lung cancer, liver cancer, pancreatic cancer, colon cancer, prostate cancer, etc. it also has a synergistic anti-cancer effect with many anti-cancer drugs, revealing the mechanism of its more complex anti-tumor pharmacological action System. In this review, we summarized a variety of anti-cancer signaling pathways and targets. Geraniol is considered to be a safe, effective and promising multi-target anti-cancer drug, which is expected to become an important force in the anti-cancer of traditional Chinese medicine.

Download Full-text

Probiotics for the Treatment of Docetaxel-Related Weight Gain of Breast Cancer Patients—A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Trial

Frontiers in Nutrition ◽

10.3389/fnut.2021.762929 ◽

2021 ◽

Vol 8 ◽

Author(s):

Zhang Juan ◽

Zhang Qing ◽

Liang Yongping ◽

Liyuan Qian ◽

Wei Wu ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Weight Gain ◽

Cancer Treatment ◽

Cancer Patients ◽

Body Fat ◽

Breast Cancer Treatment ◽

Body Fat Percentage ◽

Breast Cancer Patients ◽

Fat Percentage

Background: Docetaxel is an important chemotherapy-agent for breast cancer treatment. One of its side-effects is weight gain, which increases the all-cause mortality rate. Considering gut microbiota is one important factor for weight regulation, we hypothesized that probiotics could be potentially used to reduce the docetaxel-related weight gain in breast cancer patients.Methods: From 10/8/2018 to 10/17/2019, 100 breast cancer (Stage I-III) patients underwent four cycles of docetaxel-based chemotherapy were enrolled and randomly assigned to receive probiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) or placebo (supplementary material of the probiotics capsule) treatment for 84 days with three capsules per time, twice/day. The primary outcome: the changes in body weight and body-fat percentage of the patients were measured by a designated physician using a fat analyzer, and the secondary outcomes: the fasting insulin, plasma glucose, and lipids were directly obtained from the Hospital Information System (HIS); The metabolites were measured using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS); The fecal microbiome was analyzed using bacterial 16S ribosomal RNA (rRNA) gene sequence. All indicators were measured 1 day before the first cycle of docetaxel-based chemotherapy and 21 days after the last cycle of docetaxel-based chemotherapy.Results: Compared with the placebo group, the probiotic group showed significantly smaller changes in body weight (Mean [SD] 0.77 [2.58] vs. 2.70 [3.08], P = 0.03), body-fat percentage (Mean [SD] 0.04 [1.14] vs. 3.86 [11.09], P = 0.02), and low density lipoprotein (LDL) (Mean [SD]−0.05[0.68] vs. 0.39 [0.58], P = 0.002). Moreover, five of the 340 detected plasma metabolites showed significant differences between the two groups. The change of biliverdin dihydrochloride (B = −0.724, P = 0.02) was inverse correlated with weight gain. One strain of the phylum and three strains of the genus were detected to be significantly different between the two groups. Also, the changes of Bacteroides (B = −0.917, P < 0.001) and Anaerostipes (B = −0.894, P < 0.001) were inverse correlated with the change of LDL.Conclusions: Probiotics supplement during docetaxel-based chemotherapy for breast cancer treatment may help to reduce the increase in body weight, body-fat percentage, plasma LDL, and minimize the metabolic changes and gut dysbacteriosis.Clinical Trial Registration:http://www.chictr.org.cn/showproj.aspx?proj=24294, ChiCTR-INQ-17014181.

Download Full-text

Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor‐bearing balb/c mice

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2021-0028 ◽

2021 ◽

Vol 0 (0) ◽

Author(s):

Davar Amani ◽

Elham Shakiba ◽

Ehsan Motaghi ◽

Hiva Alipanah ◽

Mahshad Jalalpourroodsari ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Serum Level ◽

Tumor Volume ◽

Treated Group ◽

The Body ◽

Ki 67 ◽

Tumor Bearing ◽

Anti Cancer ◽

Ifn Γ

Abstract Background Psoralidin as a compound of the Psoralea corylifolia seeds exhibited several anti-cancer potentials in various cancers. Materials and methods In this study, 4T1 tumor‐bearing Balb/c mice were treated by intraperitoneal administration of Psoralidin, and Paraffin, as a control group to investigate anti-tumor, anti-angiogenic, and immunostimulatory activities in breast cancer. Body weight and tumor volume measurement were performed. Hematoxylin and Eosin (H&E) staining as well as immunohistochemistry for Ki-67, CD31 and VEGF markers were conducted. In addition, ELISA assay was performed for evaluating the serum level of IFN-γ and IL-4. Moreover, real time assay was performed to evaluate the expression of angiogenesis and immunostimulatory related genes. Results There were no significant changes in the body weight of all animal groups. The anti-cancer effects of Psoralidin were significantly observed after 24 days of the last treatment, confirmed by smaller tumor volume and also H&E staining. The expression level of Ki‐67, CD31 and VEGF were significantly decreased in tumor tissues of the Psoralidin-treated group in comparison with Paraffin-treated group. Moreover, there was a significant reduction in the serum level of IL-4 in tumor-bearing mice after Psoralidin treatment while the serum level of IFN-γ was significantly augmented in all groups. Moreover, the reduction in expression of VEGF-a and IL-1β was observed. Interestingly Psoralidin treatment led to expression increase of FOXp3. Conclusions Psoralidin shows the anti-cancer potential in an animal model of breast cancer; however, further studies are recommended to elucidate its mechanisms of action.

Download Full-text

Development of a Cationic Amphiphilic Helical Peptidomimetic (B18L) As A Novel Anti-Cancer Drug Lead

Cancers ◽

10.3390/cancers12092448 ◽

2020 ◽

Vol 12 (9) ◽

pp. 2448 ◽

Cited By ~ 1

Author(s):

Yuan Lyu ◽

Steven Kopcho ◽

Folnetti A. Alvarez ◽

Bryson C. Okeoma ◽

Chioma M. Okeoma

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Cancer Progression ◽

Cancer Drug ◽

Cancer Cell Death ◽

Drug Lead ◽

Anti Cancer ◽

Cancer Agent ◽

Caspase Substrate ◽

Dynamics Simulations

BST-2 is a novel driver of cancer progression whose expression confers oncogenic properties to breast cancer cells. As such, targeting BST-2 in tumors may be an effective therapeutic approach against breast cancer. Here, we sought to develop potent cytotoxic anti-cancer agent using the second-generation BST-2-based anti-adhesion peptide, B18, as backbone. To this end, we designed a series of five B18-derived peptidomimetics. Among these, B18L, a cationic amphiphilic α-helical peptidomimetic, was selected as the drug lead because it displayed superior anti-cancer activity against both drug-resistant and drug-sensitive cancer cells, with minimal toxicity on normal cells. Probing mechanism of action using molecular dynamics simulations, biochemical and membrane biophysics studies, we observed that B18L binds BST-2 and possesses membranolytic characteristics. Furthermore, molecular biology studies show that B18L dysregulates cancer signaling pathways resulting in decreased Src and Erk1/2 phosphorylation, increased expression of pro-apoptotic Bcl2 proteins, caspase 3 cleavage products, as well as processing of the caspase substrate, poly (ADP-ribose) polymerase-1 (PARP-1), to the characteristic apoptotic fragment. These data indicate that through the coordinated regulation of membrane, mitochondrial and signaling events, B18L executes cancer cell death and thus has the potential to be developed into a potent and selective anti-cancer compound.

Download Full-text